---
document_datetime: 2025-11-12 15:43:46
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/iclusig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: iclusig-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6723732
conversion_datetime: 2025-12-24 16:02:12.372456
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Iclusig

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000261199 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, | 16/10/2025                          |                                             | SmPC, Annex II and PL            | In this type II variation the results of the OPTIC study with the 5-Year follow-up data with cutoff date of 15 May 2024 were submitted and the SmPC |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4, 4.8, and 5.1 of the SmPC based on final results from study OPTIC (AP24534-14-203) listed as a category 3 study in the Annex II; this is a randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses. The Package Leaflet is updated accordingly. The RMP version 23.3 has also been submitted. In addition, the MAH took the opportunity to update Annex II.   |            |     | has been amended to reflect those data. All ongoing participants have completed at least 60 months of treatment. The 5-year follow-up analysis includes approximately 4 years of additional follow up since the primary analysis (cutoff date 31 May 2020) and characterizes the long-term benefit-risk of ponatinib treatment with response-based dose reduction in participants with CP-CML who have received at least 2 prior TKIs or have a T315I mutation. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000272354 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test                                                                                                                                          | 19/06/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                                                                                                                                                                                                     |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000274983 | This was an application for a group of variations. B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.b Replacement or addition of a supplier - Accepted B.II.e.1.a Qualitative and quantitative composition - B.II.e.1.a.1. Solid pharmaceutical forms - Accepted | 27/05/2025 | N/A |